menu

Collaboration and Licensing

Creating Value for Partners through Our Innovative Next – Generation Oligonucleotide Technology

NapaJen’s breakthrough oligonucleotide drug delivery system uniquely positions the company as a partner-of-choice for biotechnology and pharmaceutical companies that are focused on nucleic acid-based drug development :

  1. Our novel immune cell-targeted oligonucleotide delivery platform provides broad opportunities for NapaJen Pharma to collaborate with companies seeking a cell-specific delivery technology to pair for development of oligonucleotide therapeutics. Learn more about collaboration opportunities. Collaboration Page
  2. Our lead clinical program, NJA-730, is a novel oligonucleotide drug that offers compelling licensing opportunities. The drug has potential therapeutic application for graft-versus-host disease (GVHD) and numerous other inflammatory immunoreactive indications. Learn more about licensing opportunities. Licensing Page